ArticleMolecular biology reports2025
Comparison of factors contributing to drug resistance and infection severity in Pseudomonas aeruginosa isolates among COVID-19 and non-COVID-19 patients.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Molecular Profiling of CRISPR-Cas System, Virulence Traits, and Antimicrobial Resistance inInternational journal of microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSARS-CoVs increase susceptibility to bacterial co-infections, with Pseudomonas aeruginosa frequently detected in COVID-19 patients. Factors such as drug resistance, mobile genetic elements, and biofilm formation further complicate these infections. This study compared these characteristics in P. aeruginosa isolates from COVID-19 and non-COVID-19 patients.
methodsDuring a one-year study, 125 P. aeruginosa isolates were collected from COVID-19 patients (37 isolates) and non-COVID-19 patients (88 isolates). They were identified using conventional microbiological methods. Antimicrobial resistance patterns and multidrug-resistant (MDR) isolates were determined according to CLSI guidelines and MDR definitions. Biofilm formation was evaluated using a microtiter plate assay, and the presence of genes related to plasmid-mediated quinolone resistance (PMQR), integrons, and biofilm formation was determined by polymerase chain reaction (PCR).
resultsThe highest resistance and susceptibility among the COVID-19 and non-COVID-19 groups were observed with imipenem (51.4% vs. 42%) and cefepime (73% vs. 64.8%), respectively. Quinolones resistance ranged from 32 to 36%. Overall, 54 isolates (43.2%) were MDR, with colistin resistance found in 50% and 37.5% of MDR isolates from COVID-19 and non-COVID-19 patients, respectively. Isolates from COVID-19 patients also showed stronger biofilm-forming ability. Among PMQR genes, only aac(6')-Ib-cr was detected (47.2% of isolates). The prevalence of aac(6')-Ib-cr, class 1 integron, and pelF genes was significantly higher in isolates from COVID-19 patients.
conclusionResistance to commonly used antibiotics from different classes, along with biofilm formation, class 1 integron, aac(6')-Ib-cr, and biofilm-associated genes, were higher in COVID-19 isolates, likely contributed to the greater severity of infections in this group.
Indexed as
Identifiers
40549117What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.